Evolent Health, Inc. (EVH)
USD 9.1
(1.28%)
USD 9.1
(1.28%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 460.47 Million USD | 45.45% |
| 2022 | 316.58 Million USD | 26.43% |
| 2021 | 250.4 Million USD | -22.01% |
| 2020 | 321.06 Million USD | -3.68% |
| 2019 | 333.32 Million USD | 11.39% |
| 2018 | 299.23 Million USD | 80.7% |
| 2017 | 165.59 Million USD | 67.25% |
| 2016 | 99.01 Million USD | 150.79% |
| 2015 | 39.48 Million USD | 0.0% |
| 2014 | - USD | 100.0% |
| 2013 | -4.34 Million USD | -48.46% |
| 2012 | -2.92 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 76.67 Million USD | 2.77% |
| 2024 Q1 | 74.6 Million USD | -26.59% |
| 2023 Q2 | 117.19 Million USD | -0.01% |
| 2023 Q4 | 101.62 Million USD | -18.33% |
| 2023 FY | 460.47 Million USD | 45.45% |
| 2023 Q3 | 124.43 Million USD | 6.17% |
| 2023 Q1 | 117.21 Million USD | 41.11% |
| 2022 FY | 316.58 Million USD | 26.43% |
| 2022 Q2 | 70.23 Million USD | -9.16% |
| 2022 Q3 | 85.96 Million USD | 22.4% |
| 2022 Q1 | 77.31 Million USD | -7.82% |
| 2022 Q4 | 83.06 Million USD | -3.38% |
| 2021 Q3 | 59.34 Million USD | 18.82% |
| 2021 Q4 | 83.87 Million USD | 41.34% |
| 2021 Q1 | 57.23 Million USD | -39.86% |
| 2021 Q2 | 49.94 Million USD | -12.74% |
| 2021 FY | 250.4 Million USD | -22.01% |
| 2020 Q3 | 81.42 Million USD | 11.82% |
| 2020 Q2 | 72.82 Million USD | 1.66% |
| 2020 FY | 321.06 Million USD | -3.68% |
| 2020 Q4 | 95.18 Million USD | 16.89% |
| 2020 Q1 | 71.63 Million USD | -11.62% |
| 2019 FY | 333.32 Million USD | 11.39% |
| 2019 Q1 | 80.31 Million USD | 0.06% |
| 2019 Q4 | 81.05 Million USD | -8.29% |
| 2019 Q3 | 88.38 Million USD | 5.75% |
| 2019 Q2 | 83.57 Million USD | 4.06% |
| 2018 FY | 299.23 Million USD | 80.7% |
| 2018 Q4 | 80.26 Million USD | 5.64% |
| 2018 Q2 | 75.29 Million USD | 11.15% |
| 2018 Q1 | 67.73 Million USD | 40.6% |
| 2018 Q3 | 75.98 Million USD | 0.91% |
| 2017 FY | 165.59 Million USD | 67.25% |
| 2017 Q4 | 48.18 Million USD | 21.57% |
| 2017 Q3 | 39.63 Million USD | 1.42% |
| 2017 Q2 | 39.07 Million USD | 0.95% |
| 2017 Q1 | 38.71 Million USD | 37.62% |
| 2016 Q1 | 20.88 Million USD | -1.98% |
| 2016 FY | 99.01 Million USD | 150.79% |
| 2016 Q4 | 28.12 Million USD | 6.93% |
| 2016 Q3 | 26.3 Million USD | 10.81% |
| 2016 Q2 | 23.73 Million USD | 13.65% |
| 2015 FY | 39.48 Million USD | 0.0% |
| 2015 Q2 | 2.52 Million USD | -76.13% |
| 2015 Q3 | 15.64 Million USD | 519.07% |
| 2015 Q4 | 21.3 Million USD | 36.21% |
| 2015 Q1 | 10.58 Million USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | -100.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q1 | 5.25 Million USD | 273.66% |
| 2014 FY | - USD | 100.0% |
| 2013 FY | -4.34 Million USD | -48.46% |
| 2013 Q4 | -3.02 Million USD | 0.0% |
| 2012 FY | -2.92 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| American Well Corporation | 94.76 Million USD | -385.933% |
| Doximity, Inc. | 424.75 Million USD | -8.409% |
| MultiPlan Corporation | 306.03 Million USD | -50.461% |
| Phreesia, Inc. | 201.74 Million USD | -128.244% |
| Teladoc Health, Inc. | 1.84 Billion USD | 75.007% |
| Veeva Systems Inc. | 1.68 Billion USD | 72.695% |